论文部分内容阅读
S-1是一种由5-氟尿嘧啶(5-FU)的前体替加氟与两种新的调节药物5-氯-2,4-二羟基吡啶(吉美嘧啶)和氧嗪酸钾(奥替拉西钾)以1∶0.4∶1的比例组成的复合抗癌新药,其在不同肿瘤中均有抗肿瘤作用。在日本,S-1已被批准用于治疗晚期胃癌、头颈部癌、直肠癌、非小细胞肺癌、转移性乳腺癌、胰腺癌和胆管癌等7类肿瘤,且作为治疗晚期胃癌的一线用药。近年来,S-1在消化道肿瘤中的报道相继出现,尤其在胃癌、胰腺癌中的大规模临床研究的报道越来越受到关注。部分研究已显示S-1单药及联合用药在消化道肿瘤中的抗癌作用相对乐观,同时毒副作用低,耐受性好,口服给药方便;另外,S-1还可作为手术患者术后辅助治疗药物。本文就S-1在消化道肿瘤中的应用及价值作一阐述。
S-1 is a compound consisting of tegafur, a precursor of 5-fluorouracil (5-FU), and two new modulating drugs, 5-chloro-2,4-dihydroxypyridine (gimeracil) Thiazide potassium) in the ratio of 1: 0.4: 1 composite anti-cancer drugs, which have anti-tumor effects in different tumors. In Japan, S-1 has been approved for the treatment of advanced gastric cancer, head and neck cancer, rectal cancer, non-small cell lung cancer, metastatic breast cancer, pancreatic cancer and cholangiocarcinoma and other 7 kinds of tumors, and as a first-line treatment of advanced gastric cancer Medication. In recent years, S-1 has been reported in gastrointestinal tumors one after another, especially in gastric cancer, pancreatic cancer in large-scale clinical studies reported more and more attention. Some studies have shown that the antitumor effect of S-1 monotherapy and combination therapy in gastrointestinal tumors is relatively optimistic with low toxic side effects, good tolerability and convenient oral administration; in addition, S-1 can also be used as surgical patients After adjuvant therapy. This article describes the use and value of S-1 in gastrointestinal tumors.